Antimicrobial wound management has evolved significantly over the past decade. Where iodine-based and silver-based products once dominated the conversation, a newer class of agents — led by PHMB (polyhexamethylene biguanide) — is gaining traction among wound care specialists for its combination of broad-spectrum efficacy and low cytotoxicity. Omnicide® Antimicrobial Gel sits squarely in this category.
This post breaks down what Omnicide® is, how PHMB works at the cellular level, what the clinical evidence shows, and how wound care centers are using it in practice today.
What Is Omnicide® Antimicrobial Gel?
Omnicide® is a topical antimicrobial wound gel formulated with PHMB as its active ingredient. It is designed to reduce microbial contamination in the wound bed while maintaining the moist environment that supports tissue healing. Unlike some traditional antiseptics, Omnicide® is engineered to be effective against a wide range of pathogens without the cytotoxic effects that can impair the body's own healing response.
It is used across a range of wound types — chronic wounds, diabetic foot ulcers, pressure injuries, post-surgical sites, and any wound where microbial burden is a concern.
How Does PHMB Work?
PHMB is a cationic polymer — meaning it carries a positive charge — that is attracted to the negatively charged membranes of bacterial cells. Once it binds to the cell membrane, it disrupts the membrane's integrity, causing leakage of cellular contents and ultimately cell death. This mechanism is effective against:
- Gram-positive bacteria including Staphylococcus aureus and MRSA
- Gram-negative bacteria including Pseudomonas aeruginosa and E. coli
- Fungi including Candida species
- Biofilm — a key driver of chronic wound stagnation
Critically, PHMB's mechanism of action is physical rather than metabolic, which means bacteria are far less likely to develop resistance to it compared to traditional antibiotics. This makes it a durable long-term option for wound management programs.
Why Low Cytotoxicity Matters
Many traditional antiseptics — including povidone-iodine and hydrogen peroxide — are effective at killing bacteria but also damage healthy tissue, fibroblasts, and keratinocytes. This creates a tradeoff: you reduce the bacterial load but also slow the healing process.
PHMB has a significantly more favorable cytotoxicity profile. At therapeutic concentrations, it targets microbial cells while leaving mammalian cells largely intact. For clinicians managing chronic wounds where healing is already compromised, this distinction is clinically meaningful.
Biofilm: The Hidden Challenge in Chronic Wounds
One of the most significant barriers to chronic wound healing is biofilm — a structured community of bacteria encased in a self-produced matrix that adheres to the wound surface. Biofilm is estimated to be present in up to 80% of chronic wounds, and it is highly resistant to both the immune system and conventional antibiotics.
PHMB has demonstrated the ability to penetrate and disrupt biofilm, making it one of the more effective topical agents for wounds where biofilm is suspected or confirmed. Omnicide®'s gel formulation supports sustained contact with the wound bed, giving the active ingredient time to work against established biofilm communities.
Practical Application: How Wound Care Centers Use Omnicide®
In clinical practice, Omnicide® is typically applied directly to the wound bed as part of a comprehensive wound care protocol. It is compatible with a range of secondary dressings and can be used alongside collagen-based products like HealPACK® for a complete wound management approach.
Common use cases include:
- Diabetic foot ulcers with signs of microbial contamination
- Pressure injuries at risk for or showing signs of infection
- Post-surgical wounds with delayed healing
- Venous leg ulcers with chronic bacterial burden
- Any wound where biofilm disruption is a treatment goal
Documentation and Reimbursement Considerations
As with any advanced wound care product, documentation is critical. Clinicians should document wound measurements, tissue type, exudate characteristics, and the clinical rationale for antimicrobial gel use at each visit. This supports clean billing and reduces the risk of claim denials under Medicare and commercial payer review.
Nu Endeavors provides clinical support alongside Omnicide® — including documentation guidance and outcome tracking resources — to help facilities get the most out of the product both clinically and financially.
Is Omnicide® Right for Your Facility?
If your wound care program is managing a significant volume of chronic wounds, diabetic ulcers, or post-surgical complications — and you are looking for an antimicrobial agent that is both clinically effective and tissue-friendly — Omnicide® is worth a serious look.
The combination of broad-spectrum coverage, biofilm disruption, low cytotoxicity, and a gel formulation that maintains wound contact makes it a strong addition to any evidence-based wound care formulary.